135814 results about "Pharmaceutical drug" patented technology

A scalable platform for orchestrating networks of specialized AI multi-agent networks that enables secure collaboration through token-based protocols and real-time result streaming with advanced dynamic chain-of-thought pruning. The central orchestration engine manages domain-specific agents, implementing sophisticated multi-branch reasoning with contribution-estimation layers that evaluate each agent's utility using Shapley value-inspired metrics. The system employs information-theoretic and gradient-based surprise metric to guide memory updates and dynamic reasoning expansion, preventing local minima stagnation while preserving valuable insights through adaptive forgetting mechanisms. The platform unifies Monte Carlo tree search with contribution-aware estimation to detect high-synergy expert combinations while maintaining privacy through partial data approaches. It scales across distributed computing environments, enabling complex collaborative tasks like materials discovery, product engineering and manufacturing process design, biomedical research, and drug development. The system supports multi-party economic rewards through systematic contribution effort, cost and importance tracking, while standardized interfaces manage security, privacy, and policy constraints across heterogeneous agents.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention, which relates to the technical field of medicine inventory management, discloses an intelligent medicine inventory management and optimization system comprising a demand prediction module, an inventory monitoring module, a purchase decision module and a medicine supply module. The demand prediction module is used for performing drug demand prediction according to historical sales data, seasonal factors and market trends; and analyzing and predicting by adopting a machine learning algorithm. According to the intelligent medicine inventory management and optimization system, based on a multi-objective optimization algorithm, in combination with the inventory turnover rate, the purchase cost and the medicine validity period, a scientific and reasonable purchase replenishment strategy is generated, including purchase time, quantity and supplier selection, and the scientificity and the accuracy of a purchase decision are improved; by integrating historical sales data, seasonal factors and market trends, demand prediction is performed by using a machine learning algorithm, and an accurate drug future demand trend prediction result can be generated.

KRAS mutation inhibitors and pharmaceutical compositions comprising said inhibitors are useful for the treatment of a disease or disorder associated with KRAS mutation.

Compounds shown as formula (I) or stereoisomers thereof, or pharmaceutically acceptable salts, solvates or prodrugs thereof, a pharmaceutical composition comprising same, and the use of same in the preparation of drugs for preventing and / or treating diseases or disorders related to RAS protein activity, such as cancer.

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

Provided are a compound having the structure represented by formula (I) and capable of being used as a KRAS inhibitor, a pharmaceutical composition comprising the compound, a method for preparing the compound, and a use of the compound in treatment of cancer.

Compounds or their pharmaceutically acceptable salts can modulate the G12D mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

The present disclosure relates to a fused heteroaryl compound, a preparation method therefor, and a use thereof in medicine. Specifically, the present disclosure relates to a fused heteroaryl compound represented by general formula (I'), a preparation method therefor, a pharmaceutical composition containing said compound, and a use thereof as a therapeutic agent, especially a use thereof in the preparation of a medicament for inhibiting KRAS amplification and / or mutant activity. Each group in general formula (I') is as defined in the description.

Provided are novel compounds useful as inhibitors of KRAS, in particular KRAS G12D and / or other KRAS G12 mutants, as well as pharmaceutical compositions comprising these compounds and methods of treatment by administration of these compounds or the pharmaceutical compositions.

Provided herein are compounds, and pharmaceutically acceptable salts thereof, useful as KRAS inhibitors, methods of making and using the same (singly or in combination with additional agents), and pharmaceutical compositions thereof.

Provided herein are compounds, and pharmaceutically acceptable salts thereof, useful as KRAS inhibitors, methods of making and using the same (singly or in combination with additional agents), and pharmaceutical compositions thereof.

The present invention relates to a compound of formula (I), or a stereoisomer, a tautomer, a deuterated compound or a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition comprising the compound, and the use thereof as a drug for treating and / or preventing KRAS-mediated diseases.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

There is provided herein compounds of formula (I), (XXI), (XXII) and (XXIII) as defined herein, and salts thereof, for use in the treatment of colorectal and / or lung cancer.

The disclosure provides compounds, e.g., compounds of Formula I, and their use in treating medical diseases or disorders, such as cancer. Pharmaceutical compositions and methods of making various indene compounds are provided. The compounds are contemplated to be modulators of Ras (e.g., K-Ras).

Provided herein are KRAS proteolysis targeting chimeras (PROTACs), compositions comprising the KRAS PROTACs, and methods of making and using the KRAS PROTACs, e.g., to promote degradation of KRAS and / or treat KRAS-associated cancers. In an embodiment, the KRAS PROTAC has the structural formula (I) or a pharmaceutically acceptable salt thereof, wherein values for the variables are as described herein.

The present invention covers spirocyclic compounds of general formula (I), in which R1, R2, X, Y, and Z are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of neoplastic disorders, respectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant KRAS signaling, as a sole agent or in combination with other active ingredients.

The disclosure provides compounds, e.g., compounds of Formulae (I)-(III), and their use in treating medical diseases or disorders, such as cancer. Pharmaceutical compositions and methods of making various indene compounds are provided. The compounds are contemplated to be modulators of Ras (e.g., K-Ras).

A benzo nitrogen-containing heterocyclic derivative regulator, a preparation method therefor and a use thereof. Particularly, the present invention relates to a compound represented by general formula (XIX), a preparation method therefor, a pharmaceutical composition containing the compound, and a use of the compound as a regulator in the preparation of drugs for treating metabolic diseases and related diseases, wherein each substituent in the general formula (XIX) is the same as the definition in the description.

There is provided herein a compound of formula (I) wherein R1, R2, R3, R4, A, X1, Y, L, Z, R5, R6a, R6b, W and R7 are as defined herein, for use in the treatment of colorectal and / or lung cancer.

A compound as represented by formula I-1, a stereoisomer or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing same, and the use thereof as a PARP-1 inhibitor in the preparation of a drug for treating related diseases. Each group in formula I-1 is as defined in the description.

Provided herein are compounds, such as compounds of Formula (I), Formula (l-A), Formula (l-AA), or Formula (l-BB), or pharmaceutically acceptable salts of any one thereof, useful for modulating KRAS GD12 and / or other G12 mutants.

A fused ring compound, a pharmaceutical composition comprising same, and the use thereof. The compound has a structure as represented by formula (I), or is a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer or a mixture form thereof, a metabolite, a metabolic precursor, an isotope-substituted form, a pharmaceutically acceptable salt, a hydrate, a solvate, a polymorph or a co-crystal thereof. The compound can be used for treating one or more cancers caused by KRAS mutation.

The present invention discloses substituted 2-amino-9-(3,3-difluoropiperidin-4-yl)-7,9-dihydro-8H-purin-8-one compounds compounds having the structural formula represented by formula (I)： The substituted 2-amino-9-(3,3-difluoropiperidin-4-yl)-7,9-dihydro-8H-purin-8-one compounds, derivatives and pharmaceutically acceptable salts thereof of the present invention are capable of acting as a drug characteristic of a protein kinase inhibitor, in particular for the expression of a protein through a DNA-dependent protein kinase (DNA-PK) and can be used to treat or prevent disorders associated with abnormal protein kinase activity, such as cancer, cancer with brain metastases, cancer with meningeal metastases, glioma, glioblastoma, DIPG, and the like either as monotherapy or combination with other treatments, such as radiation therapy or chemotherapy.

The disclosure relates to methods, compositions, and combinations for the treatment of endometrial cancer. Specifically, the disclosure relates to methods of treating endometrial cancer in a subject in need thereof, comprising administering to the subject one or more chemotherapy agents, an anti-PD-L1 antibody or an antigen-binding fragment thereof, and optionally a PARP inhibitor. The disclosure also relates to combinations for use in the treatment of endometrial cancer comprising one or more chemotherapy agents, an anti-PD-L1 antibody or an antigen-binding fragment thereof, and optionally a PARP inhibitor.

The invention relates to the technical field of medicines, and provides a use of a heterocyclic anti-tumor compound, in particular a use of the heterocyclic anti-tumor compound in the preparation of a medicine for preventing and / or treating tumors or cancers. The compound has a tri-heterocyclic structure (for example, a structure as shown in formula (B)), has a novel structure, and provides a new direction for the development of SOS1 inhibitor drugs.

The invention provides a lipidosome, a preparation method thereof and application of the lipidosome in preparation of a medicine for treating PARP inhibitor-resistant breast cancer, and relates to the technical field of biology. The preparation method of the liposome provided by the invention comprises the following steps: under a stirring condition, injecting an ethanol solution dissolved with soybean phospholipid and cholesterol into a histidine aqueous solution for hydration, volatilizing an ethanol component after the hydration is finished, and carrying out ultrasonic treatment to prepare the liposome. The preparation method is simple and convenient, and the prepared liposome loaded with histidine is high in encapsulation efficiency. The research of the inventor finds that histidine metabolism reprogramming occurs in the PARPi resistance process of breast cancer cells, so that DNA synthesis repair is maintained. And after the PARPi-resistant breast cancer cells are treated by adopting the liposome disclosed by the invention, the histidine content in the breast cancer cells can be increased, so that the PARPi-resistant cells are sensitive to PARPi, and further the treatment on the PARPi-resistant breast cancer is realized.

A pyrimido-pyridine compound, a pharmaceutical composition thereof and the use thereof. The compound and the pharmaceutical composition thereof as KRAS G12D inhibitors can be used for preparing a drug for preventing or treating KRAS G12D-related diseases, and can be particularly used for preparing a drug for preventing or treating cancers.